EIC funding RNA-based cancer therapies. By Vector Bioscience Cambridge and Astrazeneca - European Innovation Council – EIC Transition Grant (2023-2026). Funding 2.5M€	Controlled Release Society CRS 4th Young Scientific Meeting of CRS-SPLC at i3S-UPorto (Feb 2023)	ACS Materials Au: Announcing the 2022 Rising Stars in Materials Science As the Editors of ACS Materials Au, we are excited to share with you our inaugural Rising Stars in Materials Science! These 17 early career materials researchers from around the world are pushing scientific boundaries, conducting impactful research at the forefront of fundamental or applied research, and interfacing with other disciplines.
Meet Dr Joao Conde @CNanolab ⭐An ACS Materials Au 2022 Rising Star⭐ The main focus of our research is the use of Cancer Nanotechnology for Precision Medicine in order to tackle crucial medical problems involved in the development of novel and highly effective diagnostic and therapy platforms for cancer. (J. Conde)	World’s Top 2% Scientists list So happy and honored to be part of the "World’s Top 2% Scientists list" by Stanford University as scientists with the most impact in 2021. Thank you so much to all @CNanolab, NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa and collaborators around the world who helped make this achievement possible	Presentation @COLife community meeting 2022 the COLife Community Meeting 2022 aims to bring together directors, group leaders, postdocs, students, technicians, staff and heads of facilities and technical platforms, all members of our community, who are eager to share their experience and know-how.
NOVA Sustainability Week 2022 Round-table conversation at Universidade Nova de Lisboa in NOVA SUSTAINABILITY WEEK - Nova Medical School #NMSResearch	Forbes - Study Evaluates Global Burden Of Cancer Based On Preventable Risk Factors This past week, The Lancet published findings reported by the “Global Burden of Disease Study 2019,” elucidating which preventable risks impact both cancer-related illness and cancer-related death throughout the world. The study group, which collected data from multiple publicly-accessible vital registry databases globally, analyzed both cancer-related deaths as well as cancer-related disease burden over the period 2010-2019.	What are the standards for Nanomedicine? This research was performed in collaboration with Technion — Israel Institute of Technology, iChEM from University of Science and Technology of China and the Center for Nanomedicine and Department of Anesthesiology from Harvard Medical School. The full article, Nanodelivery of nucleic acids, can be found in Nature Reviews Methods Primers journal. It was also highlighted by the journal in the feature PrimeView.
Conde NanoLab @Nova Medical School The Lab thanks the >1500 collaborators and co-authors	Publico - Mortes por cancro subiram 20% no mundo numa década. Em Portugal foi 10% “Este aumento mundial do número de casos e de mortes é muito significativo. Dez anos é um período curto. Estes resultados são uma grande chamada de atenção para a necessidade de aumentar a prevenção em todos os tipos de cancro”, diz ao PÚBLICO João Conde, professor e investigador da Nova Medical School e um dos especialistas deste consorcio internacional, reforçando que estes retratos permitem aos governos tomar medidas que ajudem a travar o peso da doença, como o reforço de rastreios.	Potencial Terapêutica com Nanopartículas para o Tratamento do Cancro da Mama João Conde, investigador principal do grupo Nanomedicina em Cancro na NOVA Medical School, publicou um estudo na revista Advanced Healthcare Materials, em que são avaliadas as potencialidades de um novo sistema terapêutico de nanopartículas para o tratamento do cancro da mama.
CEDOC joins consortium aiming to fight inequalities in health access worldwide João Conde, leader of the Cancer NanoMedicine lab at CEDOC, is one of the contributors of a new The Lancet publication on Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019.	Diário de Noticias - João Conde João Conde, professor de Genética, investigador do Centro de Estudos de Ciências Médicas (ToxOmics), da Faculdade de Ciências Médicas, Universidade Nova de Lisboa, defende que as farmacêuticas devem apoiar a investigação e que a nanomedicina é uma aposta de futuro.	A new meta-analysis sheds light on the progress of nanotechnology across the globe João Conde, from the Cancer Nanomedicine lab at CEDOC, just published a meta-analysis on the progress and investment in nanotechnology, alongside colleagues from iMed from Universidade de Lisboa and i3S from Universidade do Porto, MIT (United States of America) and University of Wollongong (Australia). The research was published on ACS Nano with the title “Facts and Figures on Materials Science and Nanotechnology Progress and Investment”.
ERC 10 000 Grantees What being and ERC meant for João Conde | CEDOC-NMS	J.Conde Lab | What is the present (and the future) of Nanomedice in the treatment of Cancer? Bárbara Mendes, Diana Sousa and João Conniot are all first authors of a brand new review article in Trends in Cancer, supervised by Doctor João Conde at the Cancer Nanomedicine Lab, part of the ToxOmics research unit. They describe the latest developments in the use of nanoparticle-based technology for the treatment of cancer, particularly in the need to overcome the instrinsic variations in the tumor microenvironment.	Indian Long Pepper Plant Packs Punch against Glioblastoma in Animal Model Cancers such as glioblastoma are difficult to treat because drug molecules that cross from the bloodstream into the brain are needed. The researchers developed a hydrogel-type scaffold that could be filled with piperlongumine and implanted. In two different glioblastoma mouse models, they demonstrated that their piperlongumine-filled scaffold destroyed the glioblastomas almost completely and greatly extended mouse survival compared to untreated mice.
Nanomaterials 2020 Young Investigator Award MDPI, Nanomaterials Journal	CEDOC researchers stand out in the top 2% of the most cited authors in their field CEDOC researchers Miguel Seabra, principal investigator of Molecular Mechanisms of Disease group, Pedro Póvoa, from Integrated Pathophysiological Mechanisms group, and Winchil Vaz, from Lysosomes in Chronic Human Pathology and Infection group, integrate the group of the most cited scientists worldwide in different disciplines, ranking in the top 2% in their respective fields. João Conde, from Cancer Nanomedicine group, presently working at CEDOC, also integrates this list.	Q&A Spotlight on early-career researchers Nature Communications Biology - “Swallowing the doctor”: an interview with João Conde about the future of nanomedicine
Recent Nanotechnology Applications to Combat the SARS-CoV-2 Pandemic AZO NANO Editorial Feature	RTP News João Conde ganha prémio ERC Um milhão de euros para pesquisa portuguesa de novas terapias do cancro de mama	EXPRESSO News Estudos portugueses sobre fake news e sobre terapia do cancro da mama ganham bolsas milionárias do Conselho Europeu de Investigação
PUBLICO News Cancro da mama e fake news trazem 2,9 milhões de euros de bolsas europeias	IMM News Conselho Europeu de Investigação distingue investigador do IMM	Wellcome Image Awards 2017 MicroRNA scaffold cancer therapy. Credit: João Conde, Nuria Oliva and Natalie Artzi
MIT News September 2016 Gene therapy technique may help prevent cancer metastasis. Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.	MIT News July 2016 Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results. In mice, device destroyed colorectal tumors and prevented remission after surgery.	Science Translational Medicine Science Translational Medicine Highlight - Editors' Choice in Cancer - Triple threat to colorectal cancer
Brigham and Women's Hospital Press Releases Triple-Therapy Patch Delivers Local Treatment, Prevents Recurrence in Colon Cancer Model	MIT Webpage Dec 8 2015 RNA triplex scaffolds featured on MIT webpage MicroRNA delivery: Researchers find a new way to deliver microRNAs for breast cancer treatment	Nature Materials Frontpage RNA delivery. João Conde et al. Tissue-adhesive scaffolds made by the conjugation of RNA triple helices to dendrimers lead to ~90% shrinkage of tumours two weeks after implantation in a triple-negative breast cancer mouse model.
MIT News December 2015 MIT researchers developed this hydrogel embedded with triple helix microRNA particles and used it to treat cancer in mice. microRNA nanoparticles can light up green or red when they encounter their target.	MIT News December 2015 A new way to deliver microRNAs for cancer treatment. Scientists exploit gene therapy to shrink tumors in mice with an aggressive form of breast cancer.	Science Translational Medicine Science Translational Medicine Highlight - Editors' Choice in Cancer Nanotechnology - Efficacy by design
BioTechniques News "The Incredible Shrinking Tumor" New technology applies cancer-fighting microRNAs directly to tumors, which could significantly reduce side effects of treatment.	NCI image award 2016 National Cancer Institute Image award: Cancer close up, USA. Credit: João Conde, Nuria Oliva, Natalie Artzi	BWH Clinical & Research News Shrinking Tumors with an RNA Triple-Helix Hydrogel Glue. Researchers at Brigham and Women’s Hospital (BWH) have developed an efficient and effective delivery vehicle for gene therapy, and have used it to shrink tumors by nearly 90 percent in a pre-clinical model of triple-negative breast cancer.
MIT News March 2015 Part II Hydrogel embedded with gold nanoparticles coated with DNA targeting	Nature Reviews Drug Discovery 2015 RESEARCH HIGHLIGHT in Nature Reviews Drug Discovery May 2015 Multifunctional nanodevice reverses drug resistance	Cosmos Magazine March 2015 A gold Trojan nano-horse that fights cancer. Gold nanoparticles designed to kill cancer cells are showing promise.
Sneaky 'nanobeacon' delivers smackdown to cancer cells' defenses By silencing a mechanism that allows cancer cells to reject anti-cancer drugs, a new breakthrough out of MIT and Harvard could dramatically increase the efficacy of treatment.	Antibody-drug Gold Nanoantennas in GLOBAL MEDICAL DISCOVERY